Lipoprotein oxidation in cardiovascular disease: chief culprit or innocent bystander?
Oxidation of low-density lipoprotein (LDL) is thought to contribute to atherosclerosis and cardiovascular disease. Consistent with this idea, the antioxidant drug probucol reduces the risk of restenosis, a form of cardiovascular disease, in humans. However, a new study now suggests that the protective effect of probucol depends not on its ability to inhibit lipid oxidation, but on its ability to induce the stress-induced antiinflammatory enzyme heme oxygenase (HO)-1. This might explain why other antioxidants, such as vitamin E, fail to prevent cardiovascular disease in humans.
Heinecke
Jay W
JW
Department of Medicine, University of Washington School of Medicine, Seattle, WA 98195, USA. heinecke@u.washington.edu
D002318:Cardiovascular Diseases / Q000139:chemically induced / Q000378:metabolism*; D006801:Humans; D008074:Lipoproteins / Q000009:adverse effects* / Q000378:metabolism*; D010084:Oxidation-Reduction
D008074:Lipoproteins